Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Recent lab-based discoveries suggest that IDO (indoleamine 2,3-dioxygenase) and BTK (Bruton's tyrosine Kinase) form a closely linked metabolic checkpoint in tumor-associated antigen-presenting cells. The central clinical hypothesis for the GCC2020 study is that combining ibrutinib (BTK-inhibitor) with indoximod (IDO-inhibitor) during chemotherapy will synergistically enhance anti-tumor immune responses, leading to improvement in clinical response with manageable overlapping toxicity. The GCC2020 trial is a prospective open-label phase 1 trial to determine the best safe dose of the BTK-inhibit

Trial Details

NCT ID
NCT05106296
Phase
PHASE1
Sponsor
Theodore S. Johnson
Status
RECRUITING
Cancer Type
Glioblastoma (GBM) Brain Cancer
Interventions
  • Indoximod
  • Ibrutinib
  • Cyclophosphamide
  • Etoposide
  • Temozolomide
Locations (sample)
  • Augusta, Georgia, United States|33.47097,-81.97484

Key Eligibility Criteria

  • Diagnosis:
  • Patients must have prior documented progressive or refractory disease with histologically proven initial diagnosis of ependymoma, medulloblastoma, …
  • Metastatic disease is acceptable.
  • Patients must have MRI confirmation (with and without gadolinium contrast) of current active disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Glioblastoma (GBM) Brain Cancer Trials on Trialify →